180 related articles for article (PubMed ID: 20153264)
1. Postimplant rectal dosimetry is not dependent on 103Pd or 125I seed activity.
Merrick GS; Sylvester J; Grimm P; Allen ZA; Butler WM; Reed JL; Khanjian J
Brachytherapy; 2011; 10(1):35-43. PubMed ID: 20153264
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Pro-Qura Database: rectal dose, implant quality, and brachytherapist's experience.
Loiselle CR; Waheed M; Sylvester J; Allen ZA; Grimm PD; Eulau S; Butler WM; Merrick GS
Brachytherapy; 2009; 8(1):34-9. PubMed ID: 19056321
[TBL] [Abstract][Full Text] [Related]
4. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125.
Shirvani SM; Kudchadker RJ; Bruno TL; Likhacheva A; Swanson DA; Frank SJ
Brachytherapy; 2011; 10(4):269-74. PubMed ID: 21296031
[TBL] [Abstract][Full Text] [Related]
5. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
6. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
7. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077
[TBL] [Abstract][Full Text] [Related]
8. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
9. Effect of prostatic edema on CT-based postimplant dosimetry.
Dogan N; Mohideen N; Glasgow GP; Keys K; Flanigan RC
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):483-9. PubMed ID: 12023153
[TBL] [Abstract][Full Text] [Related]
10. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding.
Mueller A; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1047-52. PubMed ID: 15234038
[TBL] [Abstract][Full Text] [Related]
11. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
[TBL] [Abstract][Full Text] [Related]
12. Influence of Pro-Qura-generated plans on postimplant dosimetric quality: a review of a multi-institutional database.
Allen Z; Merrick GS; Grimm P; Blasko J; Sylvester J; Butler W; Chaudry UU; Sitter M
Med Dosim; 2008; 33(3):206-14. PubMed ID: 18674685
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
14. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
15. Refining prostate seed brachytherapy: Comparing high-, intermediate-, and low-activity seeds for I-125 permanent seed prostate brachytherapy.
Delouya G; Bahary P; Carrier JF; Larouche RX; Hervieux Y; Béliveau-Nadeau D; Donath D; Taussky D
Brachytherapy; 2015; 14(3):329-33. PubMed ID: 25630619
[TBL] [Abstract][Full Text] [Related]
16. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.
Yue N; Dicker AP; Corn BW; Nath R; Waterman FM
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):447-54. PubMed ID: 10030274
[TBL] [Abstract][Full Text] [Related]
17. Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of the Pro-Qura database.
Orio PF; Merrick GS; Grimm P; Blasko J; Sylvester J; Allen ZA; Butler WM; Chaudhry UU
Am J Clin Oncol; 2008 Dec; 31(6):523-31. PubMed ID: 19060582
[TBL] [Abstract][Full Text] [Related]
18. The effect of obesity on rectal dosimetry after permanent prostate brachytherapy.
Patil N; Crook J; Saibishkumar EP; Aneja M; Borg J; Pond G; Ma C
Brachytherapy; 2009; 8(2):218-222. PubMed ID: 19230790
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M; Shigematsu N; Kubo A
Brachytherapy; 2007; 6(4):246-53. PubMed ID: 17959425
[TBL] [Abstract][Full Text] [Related]
20. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
